Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism. Learn more.
Findings seen over three months in men with low-grade prostate cancer, hypogonadism treated with radical prostatectomy.
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...
CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...
Only men with a specific gene variant and a family history of certain cancers should be screened, experts have said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results